COVIDENZA:恩杂鲁胺降低COVID-19患者病情的多中心随机II期临床试验方案
该试验旨在评估雄激素信号抑制药恩杂鲁胺能否改善住院COVID-19患者结局,基于男性重症居多及雄激素受体信号与TMPRSS2表达相关的观察。采用2:1随机、开放标签设计,比较恩杂鲁胺联合标准治疗与标准治疗,主要终点为需机械通气或出院时间(7点序贯量表,至30天)。计划最多纳入600例。
要点
- 住院COVID-19患者2:1随机接受恩杂鲁胺160 mg/日×5天联合标准治疗或标准治疗。
- 主要终点为30天内基于7点序贯量表的机械通气需求或出院时间。
- 试验分探索期45例、延长至100例中期分析、继续至最多600例三阶段。
核心结论
- 尚不能得出恩杂鲁胺能否改善住院COVID-19患者结局的结论,该文为试验方案总结。
研究设计与样本
- 多中心、前瞻性、随机、开放标签II期临床试验,2:1随机分配至恩杂鲁胺联合标准治疗组或标准治疗组。
- 纳入50岁以上、PCR确诊COVID-19住院且无需立即机械通气的男或女患者。
- 随机按中心和性别分层,区组大小6,分配比2:1,由独立统计师用SAS 9.4 PROC PLAN生成随机表。
- 计划分三阶段:探索期45例(30治疗/15对照),延长至前100例后中期分析,继续至最多600例。
主要发现
- 原文未报告试验结果,仅描述方案设计。
关键数值与推荐
- 干预:恩杂鲁胺口服160 mg(4×40 mg)/日,连续5天。
- 主要终点:纳入后至30天内需机械通气或出院的时间,采用7点序贯量表评估。
- 探索期45例(30治疗/15对照)重点评估安全性和实验室指标。
- 前100例后行中期分析以确定研究把握度。
临床怎么用
- 该方案为住院COVID-19患者提供雄激素信号抑制的试验性干预路径,尚待结果验证。
- 临床实践中恩杂鲁胺用于COVID-19仍属研究性质,不应常规使用。
局限性
- 开放标签设计,非安慰剂对照。
- 试验方案总结,尚无疗效和安全性结果。
- 招募曾因探索期安全性暂停而中断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The main goal of the COVIDENZA trial is to evaluate if inhibition of testosterone signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. The hypothesis is based on the observation that the majority of patients in need of intensive care are male, and the connection between androgen receptor signalling and expression of TMPRSS2, an enzyme important for SARS-CoV-2 host cell internalization. TRIAL DESIGN: Hospitalised COVID-19 patients will be randomised (2:1) to enzalutamide plus standard of care vs. standard of care designed to identify superiority. PARTICIPANTS: Included participants, men or women above 50 years of age, must be hospitalised for PCR confirmed COVID-19 symptoms and not in need of immediate mechanical ventilation. Major exclusion criteria are breast-feeding or pregnant women, hormonal treatment for prostate or breast cancer, treatment with immunosuppressive drugs, current symptomatic unstable cardiovascular disease (see Additional file 1 for further details). The trial is registered at Umeå University Hospital, Region Västerbotten, Sweden and 8 hospitals are approved for inclusion in Sweden. INTERVENTION AND COMPARATOR: Patients randomised to the treatment arm will be treated orally with 160 mg (4x40 mg) enzalutamide (Xtandi®) daily, for five consecutive days. The study is not placebo controlled. The comparator is standard of care treatment for patients hospitalised with COVID-19. MAIN OUTCOMES: The primary endpoints of the study are (time to) need of mechanical ventilation or discharge from hospital as assessed by a clinical 7-point ordinal scale (up to 30 days after inclusion). RANDOMISATION: Randomisation was stratified by center and sex. Each strata was randomized separately with block size six with a 2:1 allocation ratio (enzalutamide + "standard of care": "standard of care"). The randomisation list, with consecutive subject numbers, was generated by an independent statistician using the PROC PLAN procedure of SAS version 9.4 software (SAS Institute, Inc, Cary, North Carolina) BLINDING (MASKING): This is an open-label trial. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The trial is designed to have three phases. The first, an exploration phase of 45 participants (30 treatment and 15 control) will focus on safety and includes a more extensive laboratory assessment as well as more frequent safety evaluation. The second prolongation phase, includes the first 100 participants followed by an interim analysis to define the power of the study. The third phase is the continuation of the study up to maximum 600 participants included in total. TRIAL STATUS: The current protocol version is COVIDENZA v2.0 as of September 10, 2020. Recruitment started July 29, 2020 and is presently in safety pause after the first exploration phase. Recruitment is anticipated to be complete by 31 December 2021. TRIAL REGISTRATION: Eudract number 2020-002027-10 ClinicalTrials.gov Identifier: NCT04475601 , registered June 8, 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Welén K, Överby AK, Ahlm C, et al. COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021. PMID: 33726804. doi:10.1186/s13063-021-05137-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。